Blocking PYGO2 to overcome immunotherapy resistance in prostate cancer

Inhibiting the epigenetic regulator and oncogene PYGO2 could help treat prostate cancer by decreasing tryptophan metabolite-driven immunosuppression.

In prostate cancer patient tumor samples, higher PYGO2 expression was associated with lower CD8⁺ cytotoxic T cell infiltration, and in a retrospective analysis of a Phase II study of the anti-CTLA4 mAb Yervoy ipilimumab in metastatic castration-resistant prostate cancer (mCRPC) patients, higher PYGO2 expression was associated with shorter overall survival and progression-free survival...